Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Benefits of J&J COVID-19 vaccine outweigh risks, EU regulator says

By Sean Whooley | April 20, 2021

Johnson & JohnsonThe European Medicines Agency confirmed that the benefits of the COVID-19 vaccine from Johnson & Johnson (NYSE:JNJ) outweigh risks of blood clots.

At a meeting today, EMA’s safety committee (PRAC) concluded that there is a link between unusual blood clots with low blood platelets with the COVID-19 vaccine made by J&J’s Janssen Pharmaceuticals unit. PRAC determined that a warning for this potential issue should be added to the vaccine’s product information and the events should be listed as a very rare side effect of the vaccine, according to a news release.

The committee considered all available evidence of the events, which came to the fore after six reports of blood clots and one death in the U.S., which led to the country pausing use of J&J’s vaccine. EMA cited eight reports from the U.S. regarding blood clots among more than 7 million people who had received the J&J vaccine.

Blood clots occurred mostly at unusual sites such as in veins located in the brain (cerebral venous sinus thrombosis, CVST) and abdomen (splanchnic vein thrombosis), as well as in arteries, together with low levels of blood platelets and sometimes bleeding. EMA noted that the cases reviewed were similar to those observed with the AstraZeneca COVID-19 vaccine.

Read: 9 things to know as AstraZeneca and J&J COVID-19 vaccines face safety scrutiny

All cases occurred in people under 60 years of age within three weeks of their vaccination, with the majority affecting women. Still, based on current evidence, specific risk factors have not been confirmed.

In determining this, EMA concluded that, with COVID-19 being associated with a risk of hospitalization and death and the combination of blood clots and low blood platelets being very rare, the overall benefits of the J&J COVID-19 vaccine in preventing serious illness from infection outweigh the risks of side effects.


Filed Under: Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, Janssen Pharmaceuticals, Johnson & Johnson
 

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Related Articles Read More >

NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE